Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)

Recruiting

• Conditions: Cancer; Cancer (With or Without Metastasis)

• Registration Number: NCT07107607
• Lead Sponsor: HealthPartners Institute

Brief Summary

The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.

Detailed Description

The purpose of the study is to further assess how cannabis may help control cancer growth and attempt to validate such claims. To do this, the investigators will review medical records from consented patients who report that cannabis has helped to reduce or control growth of cancer by assessing prior cancer treatments and assessments (for example, cancer/tumor labs like prostate-specific antigen (PSA), cancer antigen (CA)-125, carcinoembryonic antigen (CEA) and radiology imaging reports such as computed tomography (CT) scan, positron emission tomography (PET)/CT scan, and magnetic resonance imaging (MRI)) as well as cannabis use details.

Study Timeline

• Study Start: 2021-03-19
• Study First Submitted: 2025-07-25
• Status Verified: 2025-08
• Study First Submitted QC: 2025-08-04
• Last Update Submitted: 2025-08-04
• Study First Posted: 2025-08-06
• Last Update Posted: 2025-08-06
• Primary Completion: 2027-01
• Study Completion: 2027-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• diagnosed with cancer
• have used any type of cannabis/marijuana, including those with cannabidiol (CBD) and/or tetrahydrocannabinol (THC) to treat their cancer
• believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker

Exclusion Criteria

• does not have cancer
• has not used any type of cannabis/marijuana, including those with CBD and/or THC to treat their cancer
• does not believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To successfully complete Phase 2 by recruiting patients to consent with a simplified screening survey.	From enrollment start to the obtainment of cancer diagnosis and treatment details and cannabis use history from each consented patient, which is estimated to take up to 6 years.	Successful completion of phase 2 of this survey study will include consenting 50 patients and obtaining their cancer and cannabis use details to validate anti-cancer claims.

Trial Locations

Locations (1)

HealthPartners Institute Cancer Research Center; 🇺🇸 Saint Louis Park, Minnesota, United States